J&J
J&J pleads guilty over children’s contaminated medicine
March 12, 2015Manufacturing and Production, Sales and Marketing FDA, J&J, JJ, McNeil, OTC, Tylenol, consta, hamburg, recall
Johnson & Johnson’s consumer division McNeil has pleaded guilty and will pay fines of $25 million for wrongdoings regarding its …
J&J leukaemia drug gets FDA go-ahead
January 30, 2015Sales and Marketing FDA, J&J, JJ, Janssen, The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s macroglobulinemia (WM) – a rare indol, Waldenström’s Macroglobulinemia, ibrutinab, imbruvica, johnson
The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s …
Scientists warn Ebola virus is mutating
January 29, 2015Research and Development, Sales and Marketing Africa, Ebola, GAVI, GSK, Institut Pasteur, J&J, JJ, guinea
Researchers in France studying the Ebola epidemic say the virus has mutated making it potentially even more contagious. Scientists based …
NICE recommends Bayer heart attack drug
January 26, 2015Sales and Marketing ACS, Bayer, J&J, JJ, NICE, Xarelto, q4, rivaroxaban
NICE has recommended Xarelto in final draft guidance as an option for preventing blood clots in people who have had …
Olysio and Xarelto boost J&J’s Q4
January 21, 2015Sales and Marketing J&J, JJ, Janssen, NICE, Remicade, Velcade, Xarelto, financials, hep C, olysio, q4, quarter four
Johnson & Johnson earned a 10% increase in worldwide sales of its drugs in the last quarter of 2014 compared …
Isis and J&J sign RNA deal
January 8, 2015Research and Development, Sales and Marketing Isis, J&J, JJ, Janssen, RNA, gastrointestinal tract
Isis Pharmaceuticals is collaborating with Johnson & Johnson’s pharma unit Janssen to develop antisense drugs to treat autoimmune disorders. The …
Vectura and J&J shake on asthma/COPD deal
January 6, 2015Research and Development, Sales and Marketing COPD, J&J, JJ, Janssen, asthma, johnson, rezolsta, tybost, vectura
British firm Vectura has entered an agreement with Johnson & Johnson’s pharma unit Janssen to develop therapies for asthma and …
Gavi pledges $300 million for Ebola vaccines
December 12, 2014Manufacturing and Production, Sales and Marketing GAVI, GSK, GlaxoSmithKline, J&J, JJ, Merck, Vaccine, WHO, newlink
The global vaccines alliance Gavi has committed to buying Ebola vaccines as soon as the World Health Organization recommends one …
Ranbaxy launches J&J biosimilar in India
December 5, 2014Manufacturing and Production, Sales and Marketing CHMP, FDA, India, J&J, JJ, Ranbaxy, Remicade, nlem, nppa
Ranbaxy has launched the first biosimilar of Johnson & Johnson’s Remicade (infliximab) in India, marking the firm’s entry into monoclonal …
J&J announces ‘major commitment’ to Ebola effort
October 22, 2014Sales and Marketing Crucell, Ebola, J&J, JJ, Vaccine, bavarian, johnson, niaid
Johnson & Johnson will invest $200 million to accelerate and significantly expand the production of its Ebola vaccine programme. The …
J&J bets $1.75 billion on virology
October 1, 2014Research and Development, Sales and Marketing AL-8176, Alios BioPharma, J&J, JJ, Janssen, sovaldi, viral
Johnson & Johnson has signed a deal to acquire Alios BioPharma, a privately-held company focussed on developing therapies for viral …
Senior J&J head appointed by Synageva
September 23, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing J&J, JJ, rob bazemore, synageva
US biopharma firm Synageva has appointed Robert Bazemore as its chief operating officer. Reporting directly to the president and chief …
New drugs see J&J sales rise
July 17, 2014Medical Communications, Sales and Marketing J&J, JJ, Q2, hepatitis C, olysio, sovaldi
Johnson & Johnson saw sales rise 9.1% to $19.5 billion year on year on the back of a strong performance …
J&J completes $4 billion OCD sale
July 2, 2014Sales and Marketing J&J, JJ, Johnson and Johnson, Ortho-Clinical Diagnostics, carlyle, ocd
Johnson & Johnson has sold its Ortho-Clinical Diagnostics (OCD) business to private equity investor The Carlyle Group for ‘approximately $4 …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
